Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_assertion type Assertion NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_head.
- NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_assertion description "[Despite increasing use of `targeted therapy,` interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_provenance.
- NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_assertion evidence source_evidence_literature NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_provenance.
- NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_assertion SIO_000772 21577143 NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_provenance.
- NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_assertion wasDerivedFrom befree-20140225 NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_provenance.
- NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_assertion wasGeneratedBy ECO_0000203 NP470931.RAmxBM9OkFRL2aHH3gNqS--RGVLtcArIbkjxz9RtxAu4Q130_provenance.